Evidence map›Paper›PMID 39629077›Full record

ArticleFrontiers in pharmacology2024

Comparison of the effects of deferasirox film-coated tablets (Jadenu

Mahya Mobinikhaledi, Vahid Falahati, Amin Tajerian, Amir Almasi Hashiani, Kazem Ghaffari, Ali Ghasemi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mahya MobinikhalediFaculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Vahid FalahatiDepartment of Pediatrics, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Amin TajerianFaculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Amir Almasi HashianiDepartment of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
Kazem GhaffariHematology and Transfusion Science Department, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Ali GhasemiDepartment of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Deferasirox (DFX) is a once-daily oral iron chelator with proven dose-dependent efficacy in patients with thalassemia major (TM). The reason for switching from DFX dispersible tablets (Exjade Method: Sixty-two patients with thalassemia over 2 years of age, who had iron overload indicated by chelation therapy, were randomly divided into two groups. The first group (n = 32) is treated with Exjade Results: The study found that 53.3% of Jadenu Conclusion: Jadenu Clinical Trial Registration: https://irct.behdasht.gov.ir/search/result?query=IRCT20210830052346N1.

Indexed as

conveniencedeferasiroxheartiron overloadliversatisfactionthalassemia major

Identifiers

PMID39629077
PMCPMC11611563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.